{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19\/CD20 CAR T-cell Therapies, in Subjects With Relapsed and\/or Refractory B-cell Lymphoma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1-open-label-multicenter-study-evaluating-the-safety-and-efficacy-of-kite-363-or-kite-753-autologous-anti-cd19-cd20-car-t-cell-therapies-in-subjects-with-relapsed-and-or-refractory-b-cell-l\/#breadcrumbitem"}]}